Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease hodgkin lymphoma
Comorbidity C0027947|neutropenia
Sentences 8
PubMedID- 21472389 Disseminated cryptococcosis in a non-hodgkin's lymphoma patient with late-onset neutropenia following rituximab-chop chemotherapy: a case report and literature review.
PubMedID- 22536253 In a phase i/ii dose-finding study, activity was observed in heavily pretreated nhl and hodgkin lymphoma (hl) patients, with neutropenia (47%) reported as the most frequent grade 3 or 4 toxicity [52].
PubMedID- 24684228 History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis.
PubMedID- 22972488 Primary prophylaxis with granulocyte colony-stimulating factor (gcsf) reduces the incidence of febrile neutropenia in patients with non-hodgkin lymphoma (nhl) receiving chop chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
PubMedID- 21687649 This paper summarizes the evidence for managing abvd-related neutropenia during the treatment of hodgkin lymphoma.
PubMedID- 22913768 Economic costs of chemotherapy-induced febrile neutropenia among patients with non-hodgkin's lymphoma in european and australian clinical practice.
PubMedID- 26532567 Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with non-hodgkin's lymphoma in greece.
PubMedID- 23452152 External validation of a risk model of febrile neutropenia occurrence in patients with non-hodgkin lymphoma.

Page: 1